AUSTIN BROWN to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications AUSTIN BROWN has written about Antimetabolites, Antineoplastic.
Connection Strength
3.855
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
Score: 0.840
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
Score: 0.816
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.
Score: 0.791
-
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
Score: 0.788
-
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025 Jul; 72(7):e31744.
Score: 0.208
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
Score: 0.201
-
Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
Score: 0.178
-
Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients. Clin Cancer Res. 2018 10 15; 24(20):5012-5017.
Score: 0.033